

#13

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Substituted heterocyclo-norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and medicaments comprising them

the specification of which was filed on December 18, 2001 as United States Patent Application.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s) for which Priority is Claimed:

Federal Republic of Germany, 10063294.7-44 of December 19, 2000

And I hereby appoint

Douglas B. Henderson, Reg.No. 20,291; Arthur S. Garrett, Reg.No. 20,338
Jerry D. Voight, Reg.No. 23,020; Herbert H. Mintz, Reg.No. 26,691;
Thomas L. Irving, Reg.No. 28,619; Thomas W. Winland, Reg.No. 27,605;
Martin I. Fuchs, Reg.No. 28,805; Susan H. Griffen, Reg.No. 30,907;
Richard B. Racine, Reg.No. 30,415; Thomas H. Jenkins, Reg.No. 30,857;
Carol P. Einaudi, Reg.No. 32,226; Frank E. Caffoe, Reg.No. 18,621;
Allen R. Jensen, Reg.No. 28,224; Bryan C. Diner, Reg.No. 32,409;
M. Paul Barker, Reg.No. 32,013; Charles E. Van Horn, Reg.No. 40,266;
David S. Forman, Reg.No. 33,694;

all of the firm of FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, Reg.No. 22,540, my attorneys, with full power of substitution and revocation to prosecute this application, to make alterations and amendments therein, to file continuation and divisional applications thereof, to receive the Patent, and to transact all business in the Patent and Trademark Office and in the Courts in connection therein, and specify that communications about the application are to be directed to the following correspondence address:

FINNEGAN, HENDERSON, FARABOW, GARRETT AND DUNNER
Franklin Square Bldg., Suite 700
1300 I Street, N.W.
Washington, DC 20005-3315
Tel. 202-408-4000



I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR(S) / Residence:

1) Dr. Uwe Heinelt, Mosbacher Straße 54, 65187 Wiesbaden, Germany

Signature: Uwe Heinelt Date: 17. 1. 2002

2) Dr. Hans-Jochen Lang, Rüdesheimer Straße 7, 65719 Hofheim, Germany

Signature: Hans-Jochen Lang Date: 17.01.2002

3) Dr. Klaus Wirth, Robert-Schumann-Ring 104, 65830 Kriftel, Germany

Signature: Klaus Wirth Date: 18.01.2002

4) Dr. Hans-Willi Jansen, Distelweg 25, 65527 Niedernhausen, Germany

Signature: Hans-Willi Jansen Date: 18.01.2002

The inventors are citizens of: 1) – 4) Germany.

Post Office Address of all Inventors: Aventis Pharma Deutschland GmbH
Patent- und Lizenzabteilung
Industriepark Höchst, Geb. K 801
65926 Frankfurt am Main, Germany